These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 26957200)
21. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Mascola JR Vaccine; 2002 May; 20(15):1922-5. PubMed ID: 11983246 [TBL] [Abstract][Full Text] [Related]
23. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. Jaworski JP; Cahn P Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003 [TBL] [Abstract][Full Text] [Related]
24. Fc receptor but not complement binding is important in antibody protection against HIV. Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298 [TBL] [Abstract][Full Text] [Related]
25. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. Zhang Z; Li S; Gu Y; Xia N Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733 [TBL] [Abstract][Full Text] [Related]
26. Antibody-mediated prevention and treatment of HIV-1 infection. Gruell H; Klein F Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968 [TBL] [Abstract][Full Text] [Related]
27. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259 [TBL] [Abstract][Full Text] [Related]
28. Harnessing Antibody-Dependent Cellular Cytotoxicity To Control HIV-1 Infection. Abuharfeil NM; Yaseen MM; Alsheyab FM ACS Infect Dis; 2019 Feb; 5(2):158-176. PubMed ID: 30525453 [TBL] [Abstract][Full Text] [Related]
29. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Klein F; Halper-Stromberg A; Horwitz JA; Gruell H; Scheid JF; Bournazos S; Mouquet H; Spatz LA; Diskin R; Abadir A; Zang T; Dorner M; Billerbeck E; Labitt RN; Gaebler C; Marcovecchio P; Incesu RB; Eisenreich TR; Bieniasz PD; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC Nature; 2012 Dec; 492(7427):118-22. PubMed ID: 23103874 [TBL] [Abstract][Full Text] [Related]
30. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847 [TBL] [Abstract][Full Text] [Related]
31. Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization? Lee WS; Kent SJ Curr Opin HIV AIDS; 2018 Mar; 13(2):160-166. PubMed ID: 29194123 [TBL] [Abstract][Full Text] [Related]
32. Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. Saunders KO; Wang L; Joyce MG; Yang ZY; Balazs AB; Cheng C; Ko SY; Kong WP; Rudicell RS; Georgiev IS; Duan L; Foulds KE; Donaldson M; Xu L; Schmidt SD; Todd JP; Baltimore D; Roederer M; Haase AT; Kwong PD; Rao SS; Mascola JR; Nabel GJ J Virol; 2015 Aug; 89(16):8334-45. PubMed ID: 26041300 [TBL] [Abstract][Full Text] [Related]
33. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429 [TBL] [Abstract][Full Text] [Related]
35. Humoral responses against HIV in male genital tract: role in sexual transmission and perspectives for preventive strategies. Gagneux-Brunon A; Rochereau N; Botelho-Nevers E; Lucht F; Pozzetto B; Paul S; Bourlet T AIDS; 2017 May; 31(8):1055-1064. PubMed ID: 28323750 [TBL] [Abstract][Full Text] [Related]
36. Defining the protective antibody response for HIV-1. Mascola JR Curr Mol Med; 2003 May; 3(3):209-16. PubMed ID: 12699358 [TBL] [Abstract][Full Text] [Related]
37. Prospects for a globally effective HIV-1 vaccine. Excler JL; Robb ML; Kim JH Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921 [TBL] [Abstract][Full Text] [Related]
38. Vector-mediated antibody gene transfer for infectious diseases. Schnepp BC; Johnson PR Adv Exp Med Biol; 2015; 848():149-67. PubMed ID: 25757620 [TBL] [Abstract][Full Text] [Related]
39. Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo. Deruaz M; Moldt B; Le KM; Power KA; Vrbanac VD; Tanno S; Ghebremichael MS; Allen TM; Tager AM; Burton DR; Luster AD J Infect Dis; 2016 Aug; 214(4):612-6. PubMed ID: 27357340 [TBL] [Abstract][Full Text] [Related]
40. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]